“Companies that offer analyses of future health risks based on basic genetic tests should be more transparent about the limitations of their predictions” Craig Venter.
In the recent New Scientist, Venter and four colleagues have proposed guidelines for the industry after assessing the results of scans of their own personal genomes as provided by the Californian firms 23andMe and Navigenics.. They found the companies recorded the genetic markers consistently at least 99.7 per cent of the time, but diverged on their assessment of the associated health risks. That’s similar to New Scientist’s comparison earlier this year of the results of scans from 23andMe and a third company, , Decode Genetics of Reykjavik, Iceland. In this case the genetic markers were consistently recorded 99.996 per cent of the time.